Correspondence 0001213900-24-111137 from Cellyan Biotechnology Co., Ltd (HKPD)
Cellyan Biotechnology Co., Ltd
Date: Dec. 20, 2024 · CIK: 0002007702 · Accession: 0001213900-24-111137
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282876
Letter
December 20, 2024
VIA EDGAR
To: Ms. Rucha Pandit
Ms. Mara Ransom
Ms. Nasreen Mohammed
Ms. Suying Li
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Re: Hong Kong Pharma Digital Technology Holdings Limited
Registration Statement on Form F-1
File No.: 333-282876
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Hong Kong Pharma Digital Technology Holdings Limited (the “Company”) hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. Eastern Time on December 20, 2024, or as soon as thereafter practicable.
Please contact Kevin (Qixiang) Sun of Bevilacqua PLLC, counsel to the Company, at (202) 869-0888, ext. 101, to provide notice of effectiveness, or if you have any questions or concerns regarding the foregoing. We appreciate your assistance in this matter. The Company understands that the representative of the underwriters, on behalf of the prospective underwriters of the offering, has joined in this request in a separate letter filed with the Securities and Exchange Commission today.
Very truly yours,
Hong Kong Pharma Digital Technology Holdings Limited
Show Raw Text
CORRESP
1
filename1.htm
December 20, 2024
VIA EDGAR
To:
Ms. Rucha Pandit
Ms. Mara Ransom
Ms. Nasreen Mohammed
Ms. Suying Li
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Re:
Hong Kong Pharma Digital Technology Holdings Limited
Registration Statement on Form F-1
File No.: 333-282876
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act
of 1933, as amended, Hong Kong Pharma Digital Technology Holdings Limited (the “Company”) hereby requests acceleration of
effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. Eastern Time on December 20,
2024, or as soon as thereafter practicable.
Please contact Kevin (Qixiang) Sun of Bevilacqua
PLLC, counsel to the Company, at (202) 869-0888, ext. 101, to provide notice of effectiveness, or if you have any questions or concerns
regarding the foregoing. We appreciate your assistance in this matter. The Company understands that the representative of the underwriters,
on behalf of the prospective underwriters of the offering, has joined in this request in a separate letter filed with the Securities and
Exchange Commission today.
Very truly yours,
Hong Kong Pharma Digital Technology Holdings Limited
/s/ Lap Sun Wong
By:
Lap Sun Wong
Title:
Chief Executive Officer